Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma,...
Nektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance). The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm...
In my previous idea dated 12/21/2018, "NKTR SHORT 1-Year, Historical supports show more downside.", I pegged a bottom support at $16. (I realize it dropped slightly below that last month). On 12/26/2018, I updated the idea to give a range for 12/31/2019, "Bullish/Bearish Outlook Dec 30th, 2019", pegging a Bearish sentiment at ~$16.32 and Bullish sentiment at...
Earnings beat yesterday with positive mobility in R&D, plus the regulatory committee has resumed inquiries that were previously placed on hold.
If you believe the analysts stating $NKTR above $70/share within 12 months, now would be the time to consider jumping in. You may be able to wait for lower pricing throughout the week, yet the zones are set to rise in a couple weeks. Not financial advice. Read prior ideas and you'll see I've been bearish for a bit. Enjoy.
Can't get back above 0 on MACD. Can't get back above 50 on Stoch RSI. TradingNewsNow claims an intrinsic value per share above $130. Results and Presentations seem to not be helping. I'd "like" to see $41/share, but $24/share might be more the direction of Nektar Therapeutics before a rebound. Continuing to watch sideways movements between $30-$37 in the meantime....
A prior chart, a new perspective, added analysis, down or sideways? I see more downside, yet, sideways looks plausible. Upside maybe 20% chance to $42 by June. Enjoy the chart.
After less than stellar results released last week, $NKTR drops. What do earnings look like? Guess we'll see. Charts gain my interest. $46 - $48 on the upside, $33 - $38 short term? NOT FINANCIAL ADVICE. JUST A WATCHER.
My chart is getting a bit messy, however, this one does shoe a consistent pattern on both MACD and Stochastic RSI, making this either the BEST time to BUY, or the WORST time to BUY. It may break $50/share by the end of summer, and End of February Earnings could rebound the stock up to $70+ on the Bullish Side over 3-6 months. On the Bearish side, I am still...
I zoomed in a little closer and thought this might be a bit more accurate in either scenario.
I joined NKTR at the ~12.67 in Jan. 2017. I did not see this historical chart prior to selling early 2018, and then upping the ante throughout 2018, learning more about options contracts as well. Now that I am at a loss of ~$8K, with a cost basis in the mid-40's, I see that even though Bristol-Myers Squibb made a huge investment, the trend should continue...